Appendix 5

Reviewer Relationships With Industry and Other Entities—2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults

Peer ReviewerRepresentationConsultantSpeakerOwnership/Partnership/PrincipalResearchInstitutional, Organizational or Other Financial BenefitExpert Witness
Dr. Steven M. EttingerOfficial—American College of Cardiology/American Heart Association Task Force on Practice GuidelinesNoneNoneNoneNoneNoneNone
Dr. Gregg G. FonarowOfficial—American Heart Association
  • AstraZeneca

  • Bristol-Myers Squibb/Sanofi*

  • GlaxoSmithKline*

  • Medtronic*

  • Merck*

  • Novartis*

  • Pfizer*

  • AstraZeneca

  • Bristol-Myers Squibb/Sanofi*

  • GlaxoSmithKline*

  • Medtronic*

  • Merck*

  • Novartis*

  • Pfizer*

NoneNoneNoneNone
Dr. G. HaroldOfficial—American College of Cardiology Board of TrusteesNoneNoneNoneNoneNoneNone
Dr. Robert E. HobbsOfficial—American College of Cardiology Board of GovernorsNone• Scios*NoneNoneNoneNone
Dr. Michael R. ZileOfficial—American Heart Association
  • Bristol-Myers Squibb/Sanofi

  • Enoxsive

  • Medtronic

  • Novartis

  • Orqis

  • Ortho Clinical Diagnostic

  • Synvista

NoneNone
  • Bristol-Myers Squibb/Sanofi

  • Enoxsive

  • Medtronic

  • Novartis

  • Orqis

  • Ortho Clinical Diagnostic

  • Synvista

NoneNone
Dr. Doug Campos-OutcaltOrganizational—American Academy of Family PhysiciansNoneNoneNoneNoneNoneNone
Dr. Jun R. ChiongOrganizational—American College of Chest Physicians• Roche Diagnostics• GlaxoSmithKlineNoneNoneNoneNone
Dr. Steven DurningOrganizational—American College of PhysiciansNoneNoneNoneNoneNoneNone
Dr. Kurt ElwardOrganizational—American Academy of Family PhysiciansNoneNoneNoneNoneNoneNone
Dr. Michael FelkerOrganizational—Heart Failure Society of America
  • Amgen

  • Boston Scientific

  • Corthera

  • Cytokinetics

  • Geron

  • XDS

  • Amgen

  • Cytokinetics

  • Roche Diagnostics

NoneNoneNoneNone
Dr. David D. GuttermanOrganizational—American College of Chest PhysiciansNoneNone• Johnson & Johnson*• National Institutes of Health*NoneNone
Dr. Charin L. HanlonOrganizational—American College of PhysiciansNoneNoneNoneNoneNoneNone
Dr. Thomas F. KoinisOrganizational—American Academy of Family PhysiciansNoneNoneNoneNoneNoneNone
Dr. Alan B. MillerOrganizational—Heart Failure Society of AmericaNone
  • AstraZeneca

  • Bristol-Myers Squibb

  • CV Therapeutics

  • GlaxoSmithKline

  • Novartis

  • CV Therapeutics

  • Medtronic

  • Merck

NoneNoneNone
Dr. Srinivas MuraliOrganizational—International Society of Heart and Lung TransplantationNoneNoneNone
  • Jarvik

  • Novacardiac

  • Paracor

  • Scios

  • Thoratic

  • Ventrocor

  • Boston Scientific*(salary)

  • Medtronic*(salary)

  • St. Jude's*(salary)

None
Dr. Nancy M. AlbertContent—American Heart Association Heart Failure and Transplant Committee
  • Arca biopharma

  • GlaxoSmithKline

  • Medtronic

• GlaxoSmithKlineNone
  • GlaxoSmithKline*

  • Medtronic*

NoneNone
Dr. John D. BisognanoContent—American College of Cardiology Board of GovernorsNoneNoneNoneNoneNoneNone
Dr. Javed ButlerContent—American College of Cardiology Heart Failure and Transplant CommitteeNone
  • Boehringer Ingelheim*

  • GlaxoSmithKline*

  • Novartis*

NoneNoneNoneNone
Dr. David E. LanfearContent—American College of Cardiology Heart Failure and Transplant Committee• ThoratecNoneNone
  • Merck

  • Sanofi-Aventis

NoneNone
Dr. Joann LindenfeldContent—American Heart Association Heart Failure and Transplant Committee
  • Arca biopharma

  • CV Therapeutics*

  • Medtronic

  • Sanofi-Aventis

  • Takeda

NoneNone
  • Merck

  • Somalogic

NoneNone
Dr. Wayne L. MillerContent—American Heart Association Heart Failure and Transplant CommitteeNoneNoneNoneNoneNoneNone
Dr. Judith E. MitchellContent—American Heart Association Heart Failure and Transplant Committee
  • GlaxoSmithKline

  • NitroMed

  • GlaxoSmithKline

  • NitroMed

NoneNoneNoneNone
Dr. Rick A. NishimuraContent—American College of Cardiology/American Heart Association Task Force on Practice GuidelinesNoneNoneNoneNoneNoneNone
Dr. Donna F. PetruccelliContent—American College of Cardiology Heart Failure and Transplant CommitteeNoneNoneNoneNoneNoneNone
Dr. Win Kuang ShenContent—American Heart Association Heart Failure and Transplant CommitteeNoneNoneNone• Medtronic*NoneNone
Dr. Lynn G. TarkingtonContent—American College of Cardiology/American Heart Association Task Force on Practice GuidelinesNoneNoneNoneNoneNoneNone
Dr. Emily J. TsaiContent—American College of Cardiology Heart Failure and Transplant CommitteeNoneNoneNoneNoneNoneNone

This table represents the relevant relationships with industry and other entities that were disclosed at the time of peer review. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.

  • * Significant (greater than $10 000) relationship.